✦ LIBER ✦

Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma : Effectiveness of dacarbazine

✍ Scribed by Rhona Stein; Susan Chen; Linda Reed; Heidi Richel; David M. Goldenberg

Publisher: John Wiley and Sons
Year: 2001
Tongue: English
Weight: 229 KB
Volume: 94
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.10157

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of advanced medullary thyroid

Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine

✍ Li-Teh Wu; Steven D. Averbuch; Douglas W. Ball; Andree De Bustros; Stephen B. Ba 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 692 KB

Toxicity and efficacy of combined radioi

Toxicity and efficacy of combined radioimmunotherapy and bevacizumab in a mouse model of medullary thyroid carcinoma

✍ Pierre-Yves Salaun; Caroline Bodet-Milin; Eric Frampas; Aurore Oudoux; Catherine 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB

## Abstract ## BACKGROUND: Significant antitumor effects were previously observed with radioimmunotherapy (RIT) using an anti‐carcinoembryonic antigen (CEA) monoclonal antibody (F6) labeled with iodine‐131 in medullary thyroid cancer (MTC)‐bearing nude mice. Nevertheless, no complete response was

Treatment of advanced medullary thyroid

Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α-2b and octreotide

✍ Giovanni Lupoli; Edvige Cascone; Francesco Arlotta; Giovanni Vitale; Luigi Celen 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 436 KB 👁 2 views

## BACKGROUND. The medical treatment of advanced medullary thyroid carcinoma (MTC) is still questionable. Results of chemotherapy are disappointing with almost no curative responses, few partial responses, and many side-effects. A recent report has suggested the activity of combination recombinant

Combined gemcitabine and radioimmunother

Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer

✍ Thomas M. Cardillo; Rosalyn Blumenthal; Zhiliang Ying; David V. Gold 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 French ⚖ 116 KB 👁 1 views

## Abstract MAb‐PAM4 is an anti‐MUC1 antibody that has been shown to be reactive with 85% of pancreatic adenocarcinomas with no reactivity with normal pancreas or other tissues. Initial clinical studies have shown excellent targeting with high tumor/nontumor ratios. Gemcitabine, an analog of deoxyc

Medullary thyroid carcinoma : Clinical c

Medullary thyroid carcinoma : Clinical characteristics, treatment, prognostic factors, and a comparison of staging systems

✍ Electron Kebebew; Philip H. G. Ituarte; Allan E. Siperstein; Quan-Yang Duh; Orlo 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

## Background: The clinical courses of patients with medullary thyroid carcinoma (mtc) vary, and a number of prognostic factors have been studied, but the significance of some of these factors remains controversial. ## Methods: The study group consisted of 104 patients with mtc or c-cell hyperpla

Discovery of targeting peptides for sele

Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma

✍ Miriam Böckmann; Matthias Drosten; Brigitte M. Pützer 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 228 KB

Background Adenovirus efficiently infects a broad range of target cells, thereby preventing selective gene transfer. Moreover, several cell types and tissues including primary tumors are refractory to adenoviral infection, mainly because of low expression levels of coxsackie-adenovirus receptor (CAR